Difference between revisions of "Drug index"
Jump to navigation
Jump to search
m |
m (→I) |
||
| (34 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
</div> | </div> | ||
=Guidelines= | =Guidelines= | ||
| − | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any | + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' |
'''Other [[#Interesting_and_Helpful_Links|interesting and helpful links]] can be found by clicking the link.''' | '''Other [[#Interesting_and_Helpful_Links|interesting and helpful links]] can be found by clicking the link.''' | ||
| Line 36: | Line 36: | ||
*[[Acalabrutinib (Calquence)]] | *[[Acalabrutinib (Calquence)]] | ||
*[[Aclarubicin (Aclacinomycin)]] | *[[Aclarubicin (Aclacinomycin)]] | ||
| − | *[[Adagrasib (Krazati)]] | + | *[[Adagrasib (Krazati)]] |
*[[Afatinib (Gilotrif)]] | *[[Afatinib (Gilotrif)]] | ||
*[[Aldesleukin (Proleukin)]] | *[[Aldesleukin (Proleukin)]] | ||
| Line 53: | Line 53: | ||
*[[Anastrozole (Arimidex)]] | *[[Anastrozole (Arimidex)]] | ||
*[[Ancestim (Stemgen)]] | *[[Ancestim (Stemgen)]] | ||
| + | *[[Anlotinib (Fukewei)]] | ||
*[[Apalutamide (Erleada)]] | *[[Apalutamide (Erleada)]] | ||
*[[Apatinib (Aitan)]] | *[[Apatinib (Aitan)]] | ||
| Line 80: | Line 81: | ||
*[[Benralizumab (Fasenra)]] | *[[Benralizumab (Fasenra)]] | ||
*[[Bevacizumab (Avastin)]] | *[[Bevacizumab (Avastin)]] | ||
| − | **[[Bevacizumab-adcd (Vegzelga)]] | + | **[[Bevacizumab-adcd (Vegzelga)]] |
| + | **[[Bevacizumab-aveg (Avegra)]] | ||
**[[Bevacizumab-awwb (Mvasi)]] | **[[Bevacizumab-awwb (Mvasi)]] | ||
| + | **[[Bevacizumab-aybi (Aybintio)]] | ||
**[[Bevacizumab-bvzr (Zirabev)]] | **[[Bevacizumab-bvzr (Zirabev)]] | ||
| + | **[[Bevacizumab-equi (Equidacent)]] | ||
**[[Bevacizumab-maly (Alymsys)]] | **[[Bevacizumab-maly (Alymsys)]] | ||
| − | |||
| − | |||
**[[Bevacizumab-onbe (Onbevzi)]] | **[[Bevacizumab-onbe (Onbevzi)]] | ||
| + | **[[Bevacizumab-tnjn (Avzivi)]] '''FDA approved 2023-12''' | ||
*[[Bexarotene (Targretin)]] | *[[Bexarotene (Targretin)]] | ||
*[[Bicalutamide (Casodex)]] | *[[Bicalutamide (Casodex)]] | ||
| Line 124: | Line 127: | ||
*[[Chlorambucil (Leukeran)]] | *[[Chlorambucil (Leukeran)]] | ||
*[[Chlorozotocin (DCNU)]] | *[[Chlorozotocin (DCNU)]] | ||
| − | *[[Ciltacabtagene autoleucel (Carvykti)]] | + | *[[Ciltacabtagene autoleucel (Carvykti)]] |
*[[Cisplatin (Platinol)]] | *[[Cisplatin (Platinol)]] | ||
*[[Cladribine (Leustatin)]] | *[[Cladribine (Leustatin)]] | ||
| Line 148: | Line 151: | ||
*[[Daratumumab and hyaluronidase (Darzalex Faspro)]] | *[[Daratumumab and hyaluronidase (Darzalex Faspro)]] | ||
*[[Daratumumab and vorhyaluronidase (Darzquro)]] | *[[Daratumumab and vorhyaluronidase (Darzquro)]] | ||
| − | *[[Darinaparsin (Darvias)]] | + | *[[Darinaparsin (Darvias)]] |
*[[Darolutamide (Nubeqa)]] | *[[Darolutamide (Nubeqa)]] | ||
*[[Dasatinib (Sprycel)]] | *[[Dasatinib (Sprycel)]] | ||
| Line 168: | Line 171: | ||
==E== | ==E== | ||
| + | *[[Eflornithine (Iwilfin)]] '''FDA approved 2023-12-13''' | ||
*[[Elacestrant (Orserdu)]] '''FDA approved 2023-01-27''' | *[[Elacestrant (Orserdu)]] '''FDA approved 2023-01-27''' | ||
*[[Elotuzumab (Empliciti)]] | *[[Elotuzumab (Empliciti)]] | ||
| Line 204: | Line 208: | ||
*[[Fulvestrant (Faslodex)]] | *[[Fulvestrant (Faslodex)]] | ||
*[[Furmonertinib (Ivesa)]] | *[[Furmonertinib (Ivesa)]] | ||
| − | *[[Futibatinib (Lytgobi)]] | + | *[[Futibatinib (Lytgobi)]] |
==G== | ==G== | ||
| Line 236: | Line 240: | ||
*[[Ifosfamide (Ifex)]] | *[[Ifosfamide (Ifex)]] | ||
*[[Imatinib (Gleevec)]] | *[[Imatinib (Gleevec)]] | ||
| + | *[[Imetelstat (Rytelo)]] '''FDA approved 2024-06-06''' | ||
*[[Infigratinib (Truseltiq)]] | *[[Infigratinib (Truseltiq)]] | ||
*[[Inotuzumab ozogamicin (Besponsa)]] | *[[Inotuzumab ozogamicin (Besponsa)]] | ||
| Line 269: | Line 274: | ||
*[[Leuprolide (Lupron)]] | *[[Leuprolide (Lupron)]] | ||
*[[Levoleucovorin (Fusilev)]] | *[[Levoleucovorin (Fusilev)]] | ||
| + | *[[Lifileuecel (Contego)]] '''FDA approved 2024-02-16''' | ||
*[[Lisocabtagene maraleucel (Breyanzi)]] | *[[Lisocabtagene maraleucel (Breyanzi)]] | ||
*[[Lobaplatin (D-19466)]] | *[[Lobaplatin (D-19466)]] | ||
| Line 276: | Line 282: | ||
*[[Lurbinectedin (Zepzelca)]] | *[[Lurbinectedin (Zepzelca)]] | ||
*[[Lutetium Lu 177 dotatate (Lutathera)]] | *[[Lutetium Lu 177 dotatate (Lutathera)]] | ||
| − | *[[Lutetium Lu 177 vipivotide tetraxetan (Pluvicto)]] | + | *[[Lutetium Lu 177 vipivotide tetraxetan (Pluvicto)]] |
==M== | ==M== | ||
| Line 294: | Line 300: | ||
*[[Mifamurtide (Mepact)]] | *[[Mifamurtide (Mepact)]] | ||
*[[Miriplatin (Miripla)]] | *[[Miriplatin (Miripla)]] | ||
| − | *[[Mirvetuximab soravtansine (Elahere)]] | + | *[[Mirvetuximab soravtansine (Elahere)]] |
*[[Mitomycin pyelocalyceal (Jelmyto)]] | *[[Mitomycin pyelocalyceal (Jelmyto)]] | ||
*[[Mitomycin (Mutamycin)]] | *[[Mitomycin (Mutamycin)]] | ||
| Line 301: | Line 307: | ||
*[[Mobocertinib (Exkivity)]] | *[[Mobocertinib (Exkivity)]] | ||
*[[Mogamulizumab (Poteligeo)]] | *[[Mogamulizumab (Poteligeo)]] | ||
| − | *[[ | + | *[[Momelotinib (Ojjaara)]] '''FDA approved 2023-09-15''' |
| + | *[[Mosunetuzumab (Lunsumio)]] | ||
*[[Moxetumomab pasudotox (Lumoxiti)]] | *[[Moxetumomab pasudotox (Lumoxiti)]] | ||
==N== | ==N== | ||
| − | *[[Nadofaragene firadenovec (Adstiladrin)]] | + | *[[Nadofaragene firadenovec (Adstiladrin)]] |
*[[Naxitamab (Danyelza)]] | *[[Naxitamab (Danyelza)]] | ||
*[[Necitumumab (Portrazza)]] | *[[Necitumumab (Portrazza)]] | ||
| Line 317: | Line 324: | ||
*[[Nintedanib (Vargatef)]] | *[[Nintedanib (Vargatef)]] | ||
*[[Niraparib (Zejula)]] | *[[Niraparib (Zejula)]] | ||
| − | *[[Niraparib and | + | *[[Niraparib and abiraterone (Akeega)]] '''FDA approved 2023-08-11''' |
| + | *[[Nirogacestat (Ogsiveo)]] '''FDA approved 2023-11-27''' | ||
*[[Nivolumab (Opdivo)]] | *[[Nivolumab (Opdivo)]] | ||
| − | *[[Nivolumab and relatlimab (Opdualag)]] '''FDA approved | + | *[[Nivolumab and relatlimab (Opdualag)]] |
| + | *[[Nogapendekin alfa inbakicept (Anktiva)]] '''FDA approved 2024-04-22''' | ||
*[[Non-pegylated liposomal doxorubicin (Myocet)]] | *[[Non-pegylated liposomal doxorubicin (Myocet)]] | ||
*[[Norethandrolone (Nilevar)]] | *[[Norethandrolone (Nilevar)]] | ||
| Line 331: | Line 340: | ||
*[[Ofatumumab (Arzerra)]] | *[[Ofatumumab (Arzerra)]] | ||
*[[Olaparib (Lynparza)]] | *[[Olaparib (Lynparza)]] | ||
| − | *[[Olutasidenib (Rezlidhia)]] | + | *[[Olutasidenib (Rezlidhia)]] |
*[[Olverembatinib (HQP-1351)]] | *[[Olverembatinib (HQP-1351)]] | ||
*[[Omacetaxine (Synribo)]] | *[[Omacetaxine (Synribo)]] | ||
| Line 343: | Line 352: | ||
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] | *[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] | ||
*[[Paclitaxel, polymeric micelle-bound (Genexol-PM)]] | *[[Paclitaxel, polymeric micelle-bound (Genexol-PM)]] | ||
| − | *[[Pacritinib (Vonjo)]] | + | *[[Pacritinib (Vonjo)]] |
*[[Padeliporfin (Tookad)]] | *[[Padeliporfin (Tookad)]] | ||
*[[Palbociclib (Ibrance)]] | *[[Palbociclib (Ibrance)]] | ||
| Line 390: | Line 399: | ||
*[[Regorafenib (Stivarga)]] | *[[Regorafenib (Stivarga)]] | ||
*[[Relugolix (Orgovyx)]] | *[[Relugolix (Orgovyx)]] | ||
| + | *[[Repotrectinib (Augtyro)]] '''FDA approved 2023-11-15''' | ||
*[[Retifanlimab (Zynyz)]] '''FDA approved 2023-03-22''' | *[[Retifanlimab (Zynyz)]] '''FDA approved 2023-03-22''' | ||
*[[Ribociclib (Kisqali)]] | *[[Ribociclib (Kisqali)]] | ||
| Line 430: | Line 440: | ||
==T== | ==T== | ||
| − | *[[Tabelecleucel (Ebvallo)]] | + | *[[Tabelecleucel (Ebvallo)]] |
*[[Tafasitamab (Monjuvi)]] | *[[Tafasitamab (Monjuvi)]] | ||
*[[Tagraxofusp (Elzonris)]] | *[[Tagraxofusp (Elzonris)]] | ||
| Line 439: | Line 449: | ||
*[[Tamibarotene (Amnoid)]] | *[[Tamibarotene (Amnoid)]] | ||
*[[Tamoxifen (Nolvadex)]] | *[[Tamoxifen (Nolvadex)]] | ||
| + | *[[Tarlatamab (Imdelltra)]] '''FDA approved 2024-05-16''' | ||
*[[Tasonermin (Beromun)]] | *[[Tasonermin (Beromun)]] | ||
*[[Tazemetostat (Tazverik)]] | *[[Tazemetostat (Tazverik)]] | ||
*[[Tebentafusp (Kimmtrak)]] | *[[Tebentafusp (Kimmtrak)]] | ||
| − | *[[Teclistamab (Tecvayli)]] | + | *[[Teclistamab (Tecvayli)]] |
*[[Tegafur and uracil (UFT)]] | *[[Tegafur and uracil (UFT)]] | ||
*[[Tegafur, gimeracil, oteracil (Teysuno, S-1)]] | *[[Tegafur, gimeracil, oteracil (Teysuno, S-1)]] | ||
| Line 459: | Line 470: | ||
*[[Topotecan (Hycamtin)]] | *[[Topotecan (Hycamtin)]] | ||
*[[Toremifene (Fareston)]] | *[[Toremifene (Fareston)]] | ||
| − | *[[Toripalimab ( | + | *[[Toripalimab (Loqtorzi)]] '''FDA approved 2023-10-27''' |
*[[Tositumomab and I-131 (Bexxar)]] | *[[Tositumomab and I-131 (Bexxar)]] | ||
| + | *[[Tovorafenib (Ojemda)]] '''FDA approved 2024-04-23''' | ||
*[[Trabectedin (Yondelis)]] | *[[Trabectedin (Yondelis)]] | ||
*[[Trametinib (Mekinist)]] | *[[Trametinib (Mekinist)]] | ||
| Line 470: | Line 482: | ||
**[[Trastuzumab-pkrb (Herzuma)]] | **[[Trastuzumab-pkrb (Herzuma)]] | ||
**[[Trastuzumab-qyyp (Trazimera)]] | **[[Trastuzumab-qyyp (Trazimera)]] | ||
| + | **[[Trastuzumab-strf (Hercessi)]] '''FDA approved 2024-04-29''' | ||
**[[Trastuzumab-zerc (Zercepac)]] | **[[Trastuzumab-zerc (Zercepac)]] | ||
*[[Trastuzumab and hyaluronidase (Herceptin Hylecta)]] | *[[Trastuzumab and hyaluronidase (Herceptin Hylecta)]] | ||
*[[Trastuzumab deruxtecan (Enhertu)]] | *[[Trastuzumab deruxtecan (Enhertu)]] | ||
*[[Trastuzumab emtansine (Kadcyla)]] | *[[Trastuzumab emtansine (Kadcyla)]] | ||
| − | *[[Tremelimumab (Imjudo)]] | + | *[[Tremelimumab (Imjudo)]] |
*[[Treosulfan (Ovastat)]] | *[[Treosulfan (Ovastat)]] | ||
*[[Trifluridine and tipiracil (Lonsurf)]] | *[[Trifluridine and tipiracil (Lonsurf)]] | ||
| Line 486: | Line 499: | ||
*[[Ublituximab (Briumvi)]] '''FDA approved 2023-01-06''' | *[[Ublituximab (Briumvi)]] '''FDA approved 2023-01-06''' | ||
==V== | ==V== | ||
| − | *[[Valemetostat (Ezharmia)]] | + | *[[Valemetostat (Ezharmia)]] |
*[[Valrubicin (Valstar)]] | *[[Valrubicin (Valstar)]] | ||
*[[Vandetanib (Caprelsa)]] | *[[Vandetanib (Caprelsa)]] | ||
| Line 505: | Line 518: | ||
*[[Zimberelimab (Yu Duo)]] | *[[Zimberelimab (Yu Duo)]] | ||
*[[Ziv-aflibercept (Zaltrap)]] | *[[Ziv-aflibercept (Zaltrap)]] | ||
| + | **[[Aflibercept-jbvf (Yesafili)]] '''FDA approved 2024-05''' | ||
| + | **[[Aflibercept-yszy (Opuviz)]] '''FDA approved 2024-05''' | ||
=Discontinued antineoplastics= | =Discontinued antineoplastics= | ||
| Line 573: | Line 588: | ||
*[[Adebrelimab (SHR-1316)]] | *[[Adebrelimab (SHR-1316)]] | ||
*[[Adenovirus-interferon-γ (TG-1042)]] | *[[Adenovirus-interferon-γ (TG-1042)]] | ||
| + | *[[Afamitresgene Autoleucel (ADP-A2M4)]] | ||
*[[Afuresertib (GSK-2110183)]] | *[[Afuresertib (GSK-2110183)]] | ||
*[[Agatolimod (PF-3512676)]] | *[[Agatolimod (PF-3512676)]] | ||
| Line 578: | Line 594: | ||
*[[Amatuximab (MORAb-009)]] | *[[Amatuximab (MORAb-009)]] | ||
*[[Amonafide (Quinamed)]] | *[[Amonafide (Quinamed)]] | ||
| − | |||
*[[Apocept (APG-101)]] | *[[Apocept (APG-101)]] | ||
*[[Astuprotimut-R (GSK-1572932A)]] | *[[Astuprotimut-R (GSK-1572932A)]] | ||
| Line 595: | Line 610: | ||
==C== | ==C== | ||
| + | *[[CARv3-TEAM-E T-cells]] | ||
*[[Catumaxomab (Removab)]] '''in US clinical trials''' | *[[Catumaxomab (Removab)]] '''in US clinical trials''' | ||
*[[Cediranib (Recentin)]] | *[[Cediranib (Recentin)]] | ||
| Line 605: | Line 621: | ||
*[[Dalpiciclib (SHR-6390)]] | *[[Dalpiciclib (SHR-6390)]] | ||
| + | *[[Danicopan (ALXN-2040)]] | ||
*[[Datopotamab deruxtecan (DS-1062)]] | *[[Datopotamab deruxtecan (DS-1062)]] | ||
*[[Denintuzumab mafodotin (SGN-CD19A)]] | *[[Denintuzumab mafodotin (SGN-CD19A)]] | ||
| Line 647: | Line 664: | ||
*[[Idasanutlin (RG-7388)]] | *[[Idasanutlin (RG-7388)]] | ||
*[[IMA-901]] | *[[IMA-901]] | ||
| − | |||
*[[Indatuximab ravtansine (BT-062)]] | *[[Indatuximab ravtansine (BT-062)]] | ||
*[[Ipatasertib (GDC-0068)]] | *[[Ipatasertib (GDC-0068)]] | ||
| − | |||
*[[IPH-2101]] | *[[IPH-2101]] | ||
| Line 676: | Line 691: | ||
*[[MK-2206]] | *[[MK-2206]] | ||
*[[Mocetinostat (MGCD-0103)]] | *[[Mocetinostat (MGCD-0103)]] | ||
| − | |||
*[[Motesanib (AMG-706)]] | *[[Motesanib (AMG-706)]] | ||
==N== | ==N== | ||
| − | |||
*[[Nolatrexed (Thymitaq)]] | *[[Nolatrexed (Thymitaq)]] | ||
==O== | ==O== | ||
| − | + | *[[Oblimersen (Genasense)]] | |
*[[Olaptesed pegol (NOX-A12)]] | *[[Olaptesed pegol (NOX-A12)]] | ||
*[[Onartuzumab (MetMAb)]] | *[[Onartuzumab (MetMAb)]] | ||
| Line 734: | Line 747: | ||
*[[Tasadenoturev (DNX-2401)]] | *[[Tasadenoturev (DNX-2401)]] | ||
*[[Telisotuzumab vedotin (ABBV-399)]] | *[[Telisotuzumab vedotin (ABBV-399)]] | ||
| + | *[[Tertomotide (GV-1001)]] | ||
*[[Tesetaxel (DJ-927)]] | *[[Tesetaxel (DJ-927)]] | ||
*[[Tesevatinib (XL-647)]] | *[[Tesevatinib (XL-647)]] | ||
| Line 768: | Line 782: | ||
=Supportive and other medications= | =Supportive and other medications= | ||
| − | ''This section contains supportive drugs that are either approved or investigational. Biosimilars are also indexed here, indented below their parent compound. Note that EMA approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound.'' | + | ''This section contains supportive drugs that are either approved or investigational. Biosimilars are also indexed here, indented below their parent compound. Note that EMA biosimilar approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound.'' |
==A== | ==A== | ||
| Line 802: | Line 816: | ||
==B== | ==B== | ||
| − | *[[Betibeglogene autotemcel (Zynteglo)]] | + | *[[Betibeglogene autotemcel (Zynteglo)]] |
*[[Betrixaban (Bevyxxa)]] | *[[Betrixaban (Bevyxxa)]] | ||
*[[Bismuth subsalicylate (Pepto-Bismol)]] | *[[Bismuth subsalicylate (Pepto-Bismol)]] | ||
| Line 857: | Line 871: | ||
*[[Edoxaban (Savaysa)]] | *[[Edoxaban (Savaysa)]] | ||
*[[Efanesoctocog alfa (Altuviiio)]] | *[[Efanesoctocog alfa (Altuviiio)]] | ||
| − | *[[Eflapegrastim (Rolvedon)]] | + | *[[Eflapegrastim (Rolvedon)]] |
*[[Eltrombopag (Promacta)]] | *[[Eltrombopag (Promacta)]] | ||
*[[Emicizumab (Hemlibra)]] | *[[Emicizumab (Hemlibra)]] | ||
| Line 873: | Line 887: | ||
*[[Eptifibatide (Integrilin)]] | *[[Eptifibatide (Integrilin)]] | ||
*[[Etranacogene dezaparvovec (Hemgenix)]] | *[[Etranacogene dezaparvovec (Hemgenix)]] | ||
| + | *[[Exagamglogene autotemcel (Casgevy)]] '''FDA approved on 2023-12-08''' | ||
==F== | ==F== | ||
| Line 907: | Line 922: | ||
*[[Fondaparinux (Arixtra)]] | *[[Fondaparinux (Arixtra)]] | ||
*[[Fosaprepitant (Emend for Injection)]] | *[[Fosaprepitant (Emend for Injection)]] | ||
| − | *[[Fosnetupitant (Arokaris)]] | + | *[[Fosnetupitant (Arokaris)]] |
*[[Furosemide (Lasix)]] | *[[Furosemide (Lasix)]] | ||
| Line 925: | Line 940: | ||
*[[Idarucizumab (Praxbind)]] | *[[Idarucizumab (Praxbind)]] | ||
*[[Indomethacin (Indocin)]] | *[[Indomethacin (Indocin)]] | ||
| + | *[[Iptacopan (Fabhalta)]] '''FDA approved 2023-12-05''' | ||
*[[Iron dextran (INFeD)]] | *[[Iron dextran (INFeD)]] | ||
*[[Iron sucrose (Venofer)]] | *[[Iron sucrose (Venofer)]] | ||
| Line 942: | Line 958: | ||
*[[Loperamide (Imodium)]] | *[[Loperamide (Imodium)]] | ||
*[[Lorazepam (Ativan)]] | *[[Lorazepam (Ativan)]] | ||
| + | *[[Lovotibeglogene autotemcel (Lyfgenia)]] '''FDA approved on 2023-12-08''' | ||
*[[Luspatercept (Reblozyl)]] | *[[Luspatercept (Reblozyl)]] | ||
*[[Lusutrombopag (Mulpleta)]] | *[[Lusutrombopag (Mulpleta)]] | ||
| Line 953: | Line 970: | ||
*[[Methyltesterone (Android)]] | *[[Methyltesterone (Android)]] | ||
*[[Metoclopramide (Reglan)]] | *[[Metoclopramide (Reglan)]] | ||
| − | *[[Mitapivat (Pyrukynd)]] | + | *[[Mitapivat (Pyrukynd)]] |
*[[Motixafortide (Aphexda)]] '''FDA approved 2023-09''' | *[[Motixafortide (Aphexda)]] '''FDA approved 2023-09''' | ||
*[[Mycophenolate mofetil (CellCept)]] | *[[Mycophenolate mofetil (CellCept)]] | ||
| Line 1,021: | Line 1,038: | ||
*[[Rolapitant (Varubi)]] | *[[Rolapitant (Varubi)]] | ||
*[[Romiplostim (Nplate)]] | *[[Romiplostim (Nplate)]] | ||
| + | *[[Rusfertide (PTG-300)]] | ||
==S== | ==S== | ||
| Line 1,030: | Line 1,048: | ||
*[[Sirolimus (Rapamune)]] | *[[Sirolimus (Rapamune)]] | ||
*[[Sodium thiosulfate (Pedmark)]] | *[[Sodium thiosulfate (Pedmark)]] | ||
| − | *[[Sutimlimab (Enjaymo)]] | + | *[[Sutimlimab (Enjaymo)]] |
==T== | ==T== | ||
| Line 1,074: | Line 1,092: | ||
=By Category= | =By Category= | ||
| − | ''Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is | + | ''Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is an ongoing process so not all of these links are active or current).'' |
==[[:Category:REMS_program|Drugs in a REMS program]]== | ==[[:Category:REMS_program|Drugs in a REMS program]]== | ||
| Line 1,221: | Line 1,239: | ||
*[[:Category:Anal cancer medications|Anal cancer medications]] | *[[:Category:Anal cancer medications|Anal cancer medications]] | ||
*[[:Category:Anaplastic large cell lymphoma medications|Anaplastic large cell lymphoma medications]] | *[[:Category:Anaplastic large cell lymphoma medications|Anaplastic large cell lymphoma medications]] | ||
| − | |||
*[[:Category:Bladder cancer medications|Bladder cancer medications]] | *[[:Category:Bladder cancer medications|Bladder cancer medications]] | ||
*[[:Category:Bone cancer medications |Bone cancer medications]] | *[[:Category:Bone cancer medications |Bone cancer medications]] | ||
| Line 1,227: | Line 1,244: | ||
*[[:Category:Burkitt lymphoma medications|Burkitt lymphoma medications]] | *[[:Category:Burkitt lymphoma medications|Burkitt lymphoma medications]] | ||
*[[:Category:Cancer of unknown primary medications |Cancer of unknown primary medications]] | *[[:Category:Cancer of unknown primary medications |Cancer of unknown primary medications]] | ||
| − | *[[:Category: | + | *[[:Category:Castleman disease medications|Castleman disease medications]] |
*[[:Category:Central nervous system (CNS) cancer medications|Central nervous system (CNS) cancer medications]] | *[[:Category:Central nervous system (CNS) cancer medications|Central nervous system (CNS) cancer medications]] | ||
*[[:Category:CNS lymphoma medications|Central nervous system (CNS) lymphoma medications]] | *[[:Category:CNS lymphoma medications|Central nervous system (CNS) lymphoma medications]] | ||
| Line 1,236: | Line 1,253: | ||
*[[:Category:Colon cancer medications|Colon cancer medications]] | *[[:Category:Colon cancer medications|Colon cancer medications]] | ||
*[[:Category:Colorectal cancer medications|Colorectal cancer (CRC) medications]] | *[[:Category:Colorectal cancer medications|Colorectal cancer (CRC) medications]] | ||
| + | *[[:Category:Cutaneous basal cell carcinoma medications|Cutaneous BCC medications]] | ||
| + | *[[:Category:Cutaneous squamous cell carcinoma medications|Cutaneous SCC medications]] | ||
*[[:Category:Cutaneous T-cell lymphoma medications|Cutaneous T-cell lymphoma medications]] | *[[:Category:Cutaneous T-cell lymphoma medications|Cutaneous T-cell lymphoma medications]] | ||
*[[:Category:Diffuse large B-cell lymphoma medications|Diffuse large B-cell lymphoma medications]] | *[[:Category:Diffuse large B-cell lymphoma medications|Diffuse large B-cell lymphoma medications]] | ||
| Line 1,298: | Line 1,317: | ||
*[[:Category:Subcutaneous medications|Subcutaneous (SC) medications]] | *[[:Category:Subcutaneous medications|Subcutaneous (SC) medications]] | ||
| − | ==Medications by Year of Approval== | + | ==Medications by FDA Year of Approval== |
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
| Line 1,375: | Line 1,394: | ||
*[[:Category:FDA approved in 2022|FDA approved in 2022]] | *[[:Category:FDA approved in 2022|FDA approved in 2022]] | ||
*[[:Category:FDA approved in 2023|FDA approved in 2023]] | *[[:Category:FDA approved in 2023|FDA approved in 2023]] | ||
| + | *[[:Category:FDA approved in 2024|FDA approved in 2024]] | ||
</div> | </div> | ||
Revision as of 17:57, 9 June 2024
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
Other interesting and helpful links can be found by clicking the link.
Chemotherapy safety standards
- 2020: Dillmon et al. Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards PubMed
- 2019: Celano et al. Safe handling of hazardous drugs: ASCO standards PubMed
- 2016: Neuss et al. 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology
- 2010: Carrington et al. The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy PubMed
Dose adjustments
- 2021: Griggs et al. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update
- 2012: Griggs et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline[1]
Antimicrobials
Growth factors
- 2015: Update of ASCO Clinical Practice Guideline recommendations for the use of WBC growth factors[2]
Approved antineoplastics
This section contains anticancer drugs that have had at least one formal approval in any domain (FDA, EMA, etc). Biosimilars are also indexed here, indented below their parent compound. Note that EMA biosimilar approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound. For drugs first approved within the current or prior calendar years, the date of initial approval is also provided here.
A
- Abarelix (Plenaxis)
- Abemaciclib (Verzenio)
- Abiraterone (Zytiga)
- Acalabrutinib (Calquence)
- Aclarubicin (Aclacinomycin)
- Adagrasib (Krazati)
- Afatinib (Gilotrif)
- Aldesleukin (Proleukin)
- Alectinib (Alecensa)
- Alemtuzumab (Campath)
- Alitretinoin (Panretin)
- All-trans retinoic acid (ATRA)
- Alpelisib (Piqray)
- Altretamine (Hexalen)
- Alvocidib (Flavopiridol)
- Amifostine (Ethyol)
- Aminoglutethimide (Cytadren)
- Amivantamab (Rybrevant)
- Amrubicin (Calsed)
- Amsacrine (Amsidine)
- Anastrozole (Arimidex)
- Ancestim (Stemgen)
- Anlotinib (Fukewei)
- Apalutamide (Erleada)
- Apatinib (Aitan)
- Arsenic trioxide (Trisenox)
- Asciminib (Scemblix)
- Asparaginase Erwinia chrysanthemi (Erwinaze)
- Atezolizumab (Tecentriq)
- Aumolertinib (Amelie)
- Avapritinib (Ayvakit)
- Avelumab (Bavencio)
- Axicabtagene ciloleucel (Yescarta)
- Axitinib (Inlyta)
- Azacitidine (Onureg)
- Azacitidine (Vidaza)
B
- BCG vaccine
- Belantamab mafodotin (Blenrep)
- Belinostat (Beleodaq)
- Belotecan (Camptobell)
- Belumosudil (Rezurock)
- Belzutifan (Welireg)
- Bendamustine
- Benralizumab (Fasenra)
- Bevacizumab (Avastin)
- Bexarotene (Targretin)
- Bicalutamide (Casodex)
- Binimetinib (Mektovi)
- Bleomycin (Blenoxane)
- Blinatumomab (Blincyto)
- Borofalan-10B (Steboronine)
- Bortezomib (Velcade)
- Bosutinib (Bosulif)
- Brentuximab vedotin (Adcetris)
- Brexucabtagene autoleucel (Tecartus)
- Brigatinib (Alunbrig)
- Buserelin (Suprefact)
- Busulfan (Myleran)
C
- Cabazitaxel (Jevtana)
- Cabozantinib (Cabometyx)
- Cabozantinib (Cometriq)
- Calaspargase (Asparlas)
- Camrelizumab (AiRuiKa)
- Capecitabine (Xeloda)
- Capivasertib (Truqap) FDA approved 2023-11-16
- Caplacizumab (Cablivi)
- Capmatinib (Tabrecta)
- Carboplatin (Paraplatin)
- Carfilzomib (Kyprolis)
- Carmofur (HCFU)
- Carmustine (BCNU)
- Carmustine wafer, polifeprosan 20 (Gliadel)
- Cemiplimab (Libtayo)
- Ceritinib (Zykadia)
- Cetuximab (Erbitux)
- Chidamide (Epidaza)
- Chlorambucil (Leukeran)
- Chlorozotocin (DCNU)
- Ciltacabtagene autoleucel (Carvykti)
- Cisplatin (Platinol)
- Cladribine (Leustatin)
- Clofarabine (Clolar)
- Cobimetinib (Cotellic)
- Copanlisib (Aliqopa)
- Cortisone
- Crizotinib (Xalkori)
- Cyclophosphamide (Cytoxan)
- Cyproterone acetate (Androcur)
- Cytarabine (Ara-C)
- Cytarabine and daunorubicin liposomal (Vyxeos)
- Cytarabine liposomal (DepoCyt)
D
- Dabrafenib (Tafinlar)
- Dacarbazine (DTIC)
- Dacomitinib (Vizimpro)
- Dactinomycin (Cosmegen)
- Daratumumab (Darzalex)
- Daratumumab and hyaluronidase (Darzalex Faspro)
- Daratumumab and vorhyaluronidase (Darzquro)
- Darinaparsin (Darvias)
- Darolutamide (Nubeqa)
- Dasatinib (Sprycel)
- Daunorubicin (Cerubidine)
- Decitabine (Dacogen)
- Decitabine and cedazuridine (Inqovi)
- Degarelix (Firmagon)
- Dexamethasone (Decadron)
- Dinutuximab (Unituxin)
- Dinutuximab beta (Qarziba)
- Docetaxel (Taxotere)
- Donafenib (Zepsun)
- Dostarlimab (Jemperli)
- Doxifluridine (Didox)
- Doxorubicin (Adriamycin)
- Durvalumab (Imfinzi)
- Dutasteride (Avodart)
- Duvelisib (Copiktra)
E
- Eflornithine (Iwilfin) FDA approved 2023-12-13
- Elacestrant (Orserdu) FDA approved 2023-01-27
- Elotuzumab (Empliciti)
- Elranatamab (Elrexfio) FDA approved on 2023-08-14
- Emapalumab (Gamifant)
- Enasidenib (Idhifa)
- Encorafenib (Braftovi)
- Enfortumab vedotin (Padcev)
- Ensartinib (Ensacove)
- Entrectinib (Rozlytrek)
- Envafolimab (Enweida)
- Enzalutamide (Xtandi)
- Epcoritamab (Epkinly) FDA approved 2023-05-19
- Epirubicin (Ellence)
- Erdafitinib (Balversa)
- Eribulin (Halaven)
- Erlotinib (Tarceva)
- Estradiol
- Estramustine (Emcyt)
- Etoposide (Vepesid)
- Everolimus (Afinitor)
- Exemestane (Aromasin)
F
- Fadrozole (Afema)
- Fedratinib (Inrebic)
- Fluorouracil (5-FU)
- Fludarabine (Fludara)
- Flumatinib (Xinfu)
- Flutamide (Eulexin)
- Leucovorin (Folinic acid)
- Forodesine (Fodosine)
- Fostamatinib (Tavalisse)
- Fotemustine (Muphoran)
- Fruquintinib (Elunate)
- Fulvestrant (Faslodex)
- Furmonertinib (Ivesa)
- Futibatinib (Lytgobi)
G
- Gallium Ga 68 gozetotide (Locametz)
- Gefitinib (Iressa)
- Gemcitabine (Gemzar)
- Gemtuzumab ozogamicin (Mylotarg)
- Gilteritinib (Xospata)
- Glasdegib (Daurismo)
- Glofitamab (Columvi) FDA approved 2023-06-15
- Goserelin (Zoladex)
H
- Heptaplatin (SunPla)
- Histamine dihydrochloride (Ceplene)
- Histrelin (Vantas)
- Hydrocortisone (Cortef)
- Hydroxyurea (Hydrea)
I
- Ibritumomab tiuxetan (Zevalin)
- Ibrutinib (Imbruvica)
- Icotinib (Conmana)
- Idarubicin (Idamycin)
- Idecabtagene vicleucel (Abecma)
- Idelalisib (Zydelig)
- Ifosfamide (Ifex)
- Imatinib (Gleevec)
- Imetelstat (Rytelo) FDA approved 2024-06-06
- Infigratinib (Truseltiq)
- Inotuzumab ozogamicin (Besponsa)
- Interferon alfa-2a (Roferon-A)
- Interferon alfa-2b (Intron-A)
- Interferon gamma-1a (Imunomax-γ)
- Interferon gamma-1b (Actimmune)
- Iobenguane I 131 (Azedra)
- Iodine-131
- Ipilimumab (Yervoy)
- Irinotecan (Camptosar)
- Irinotecan liposome (Onivyde)
- Isatuximab (Sarclisa)
- Isotretinoin (Accutane)
- Ivosidenib (Tibsovo)
- Ixabepilone (Ixempra)
- Ixazomib (Ninlaro)
K
L
- Lanreotide (Somatuline)
- Lanreotide LAR (Somatuline Depot)
- Lapatinib (Tykerb)
- Larotrectinib (Vitrakvi)
- Lasofoxifene (Fablyn)
- Lenalidomide (Revlimid)
- Lenvatinib (Lenvima)
- Letrozole (Femara)
- Leuprolide (Lupron)
- Levoleucovorin (Fusilev)
- Lifileuecel (Contego) FDA approved 2024-02-16
- Lisocabtagene maraleucel (Breyanzi)
- Lobaplatin (D-19466)
- Lomustine (CCNU)
- Loncastuximab tesirine (Zynlonta)
- Lorlatinib (Lorbrena)
- Lurbinectedin (Zepzelca)
- Lutetium Lu 177 dotatate (Lutathera)
- Lutetium Lu 177 vipivotide tetraxetan (Pluvicto)
M
- Margetuximab (Margenza)
- Mechlorethamine (Mustargen)
- Medroxyprogesterone acetate (MPA)
- Megestrol (Megace)
- Melphalan (Alkeran)
- Melphalan for Injection-Hepatic Delivery System (Hepzato Kit) FDA approved on 2023-08-14
- Mepolizumab (Nucala)
- Mercaptopurine (6-MP)
- Methotrexate (MTX)
- Methoxsalen (Uvadex)
- Methylprednisolone (Solumedrol)
- Midostaurin (Rydapt)
- Mifamurtide (Mepact)
- Miriplatin (Miripla)
- Mirvetuximab soravtansine (Elahere)
- Mitomycin pyelocalyceal (Jelmyto)
- Mitomycin (Mutamycin)
- Mitotane (Lysodren)
- Mitoxantrone (Novantrone)
- Mobocertinib (Exkivity)
- Mogamulizumab (Poteligeo)
- Momelotinib (Ojjaara) FDA approved 2023-09-15
- Mosunetuzumab (Lunsumio)
- Moxetumomab pasudotox (Lumoxiti)
N
- Nadofaragene firadenovec (Adstiladrin)
- Naxitamab (Danyelza)
- Necitumumab (Portrazza)
- Nedaplatin (Aqupla)
- Nelarabine (Arranon)
- Neratinib (Nerlynx)
- Nilotinib (Tasigna)
- Nilutamide (Nilandron)
- Nimotuzumab (Theraloc)
- Nimustine (ACNU)
- Nintedanib (Vargatef)
- Niraparib (Zejula)
- Niraparib and abiraterone (Akeega) FDA approved 2023-08-11
- Nirogacestat (Ogsiveo) FDA approved 2023-11-27
- Nivolumab (Opdivo)
- Nivolumab and relatlimab (Opdualag)
- Nogapendekin alfa inbakicept (Anktiva) FDA approved 2024-04-22
- Non-pegylated liposomal doxorubicin (Myocet)
- Norethandrolone (Nilevar)
- NovoTTF-100A system (Optune)
O
- Obinutuzumab (Gazyva)
- Octreotide (Sandostatin)
- Octreotide LAR (Sandostatin LAR)
- Ofatumumab (Arzerra)
- Olaparib (Lynparza)
- Olutasidenib (Rezlidhia)
- Olverembatinib (HQP-1351)
- Omacetaxine (Synribo)
- Osimertinib (Tagrisso)
- Oxaliplatin (Eloxatin)
P
- Paclitaxel (Taxol)
- Paclitaxel, nanoparticle albumin-bound (Abraxane)
- Paclitaxel, polymeric micelle-bound (Genexol-PM)
- Pacritinib (Vonjo)
- Padeliporfin (Tookad)
- Palbociclib (Ibrance)
- Panitumumab (Vectibix)
- Panobinostat (Farydak)
- Pazopanib (Votrient)
- Pegaspargase (Oncaspar)
- Peginterferon alfa-2a (Pegasys)
- Peginterferon alfa-2b (Sylatron)
- Pegylated liposomal doxorubicin (Doxil)
- Pembrolizumab (Keytruda)
- Pemetrexed (Alimta)
- Pemigatinib (Pemazyre)
- Penpulimab (Anniko)
- Pentostatin (Nipent)
- Pertuzumab (Perjeta)
- Pertuzumab and Trastuzumab hyaluronidase (Phesgo)
- Pexidartinib (Turalio)
- Pipobroman (Vercyte)
- Pirarubicin (THP)
- Pirtobrutinib (Jaypirca) FDA approved 2023-01-27
- Pixantrone (Pixuvri)
- Polatuzumab vedotin (Polivy)
- Pomalidomide (Pomalyst)
- Ponatinib (Iclusig)
- Porfimer (Photofrin)
- Pralatrexate (Folotyn)
- Pralsetinib (Gavreto)
- Prednisone (Sterapred)
- Prednisolone (Millipred)
- Procarbazine (Matulane)
- Pyrotinib (Irene)
Q
R
- Racotumomab (Vaxira)
- Radium-223 (Xofigo)
- Radotinib (Supect)
- Raltitrexed (Tomudex)
- Ramucirumab (Cyramza)
- Ranimustine (Cymerin)
- Ravulizumab (Ultomiris)
- Realgar-Indigo naturalis formulation
- Regorafenib (Stivarga)
- Relugolix (Orgovyx)
- Repotrectinib (Augtyro) FDA approved 2023-11-15
- Retifanlimab (Zynyz) FDA approved 2023-03-22
- Ribociclib (Kisqali)
- Ripretinib (Qinlock)
- Rituximab (Rituxan)
- Rituximab and hyaluronidase human (Rituxan Hycela)
- Romidepsin (Istodax)
- Ropeginterferon alfa-2b (Besremi)
- Rucaparib (Rubraca)
- Ruxolitinib (Jakafi)
S
- Sacituzumab govitecan (Trodelvy)
- Samarium-153 (Quadramet)
- Selinexor (Xpovio)
- Selpercatinib (Retevmo)
- Selumetinib (Koselugo)
- Serplulimab (Hansizhuang)
- Sintilimab (Tyvyt)
- Sipuleucel-T (Provenge)
- Sirolimus protein-bound particles (Fyarro)
- Sonidegib (Odomzo)
- Sorafenib (Nexavar)
- Sotorasib (Lumakras)
- Stilbamidine
- Streptozocin (Zanosar)
- Strontium-89 (Metastron)
- Sugemalimab (Cejemly)
- Sunitinib (Sutent)
- Suramin (Antrypol)
T
- Tabelecleucel (Ebvallo)
- Tafasitamab (Monjuvi)
- Tagraxofusp (Elzonris)
- Talazoparib (Talzenna)
- Talimogene laherparepvec (Imlygic)
- Taloporfin (Laserphyrin)
- Talquetamab (Talvey) FDA approved 2023-08-09
- Tamibarotene (Amnoid)
- Tamoxifen (Nolvadex)
- Tarlatamab (Imdelltra) FDA approved 2024-05-16
- Tasonermin (Beromun)
- Tazemetostat (Tazverik)
- Tebentafusp (Kimmtrak)
- Teclistamab (Tecvayli)
- Tegafur and uracil (UFT)
- Tegafur, gimeracil, oteracil (Teysuno, S-1)
- Temoporfin (Foscan)
- Temozolomide (Temodar)
- Temsirolimus (Torisel)
- Teniposide (Vumon)
- Tepotinib (Tepmetko)
- Thalidomide (Thalomid)
- Thioguanine (Tabloid)
- Thiotepa (Tepadina)
- Thiotepa (Thioplex)
- Tirabrutinib (Velexbru)
- Tisagenlecleucel (Kymriah)
- Tisotumab vedotin (Tivdak)
- Topotecan (Hycamtin)
- Toremifene (Fareston)
- Toripalimab (Loqtorzi) FDA approved 2023-10-27
- Tositumomab and I-131 (Bexxar)
- Tovorafenib (Ojemda) FDA approved 2024-04-23
- Trabectedin (Yondelis)
- Trametinib (Mekinist)
- Trastuzumab (Herceptin)
- Trastuzumab and hyaluronidase (Herceptin Hylecta)
- Trastuzumab deruxtecan (Enhertu)
- Trastuzumab emtansine (Kadcyla)
- Tremelimumab (Imjudo)
- Treosulfan (Ovastat)
- Trifluridine and tipiracil (Lonsurf)
- Trilostane (Vetoryl)
- Trimetrexate (Neutrexin)
- Triptorelin (Trelstar LA)
- Trofosfamide (Ixoten)
- Tucatinib (Tukysa)
U
- Ublituximab (Briumvi) FDA approved 2023-01-06
V
- Valemetostat (Ezharmia)
- Valrubicin (Valstar)
- Vandetanib (Caprelsa)
- Vemurafenib (Zelboraf)
- Venetoclax (Venclexta)
- Vinblastine (Velban)
- Vincristine (Oncovin)
- Vindesine (Eldisine)
- Vinflunine (Javlor)
- Vinorelbine (Navelbine)
- Vismodegib (Erivedge)
- Vorinostat (Zolinza)
- Voxelotor (Oxbryta)
Z
- Zanubrutinib (Brukinsa)
- Zimberelimab (Yu Duo)
- Ziv-aflibercept (Zaltrap)
- Aflibercept-jbvf (Yesafili) FDA approved 2024-05
- Aflibercept-yszy (Opuviz) FDA approved 2024-05
Discontinued antineoplastics
This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc), but are no longer on the market. Note that it is possible that these drugs continue to be available in some limited way, such as through compassionate use programs.
A
D
E
F
L
M
O
P
S
T
U
V
Investigational antineoplastics
This list is far from exhaustive. Drugs are included here generally once there are some encouraging preliminary results. Since is it very difficult to tell when a company has stopped development on a drug, this list may also include drugs that are no longer under investigation.
A
- Abexinostat (PCI-24781)
- Actinium Ac 225 lintuzumab (Actimab-A)
- Adavosertib (MK-1775)
- Adebrelimab (SHR-1316)
- Adenovirus-interferon-γ (TG-1042)
- Afamitresgene Autoleucel (ADP-A2M4)
- Afuresertib (GSK-2110183)
- Agatolimod (PF-3512676)
- Alisertib (MLN-8237)
- Amatuximab (MORAb-009)
- Amonafide (Quinamed)
- Apocept (APG-101)
- Astuprotimut-R (GSK-1572932A)
B
- Barasertib (AZD-1152)
- Bavituximab (PGN-401)
- Befotertinib (D-0316)
- Belagenpumatucel-L (Lucanix)
- BE-CAR7
- BHQ-880
- Birtamimab (NEOD-001)
- BL22 immunotoxin (CAT-3888)
- Buparlisib (BKM-120)
C
- CARv3-TEAM-E T-cells
- Catumaxomab (Removab) in US clinical trials
- Cediranib (Recentin)
- Cixutumumab (IMC-A12)
- Coltuximab ravtansine (SAR-3419)
- Crenolanib (CP-868,596)
- Custirsen (OGX-011)
D
- Dalpiciclib (SHR-6390)
- Danicopan (ALXN-2040)
- Datopotamab deruxtecan (DS-1062)
- Denintuzumab mafodotin (SGN-CD19A)
- Dinaciclib (SCH-727965)
- Divarasib (GDC-6036)
- Discodermolide (XAA-296)
- DMUC-5754A
- Dovitinib (TKI-258)
E
- Emepepimut-S (Stimuvax)
- Eluvixtamab (AMG-330)
- Entinostat (SNDX-275)
- Entospletinib (GS-9973)
- Envonalkib (TQ-B3139)
- Epratuzumab (LymphoCide)
- Etirinotecan pegol (NKTR-102)
F
G
- G207
- Galeterone (TOK-001)
- Galunisertib (LY-2157299)
- Ganetespib (STA-9090)
- Ganitumab (AMG-479)
- GD2-CART01
- Gemcitabine elaidate (CP-4126)
- Glembatumumab vedotin (CDX-011)
- Guadecitabine (SGI-110)
H
I
J
L
- Lapuleucel-T (DN24-02)
- Lestaurtinib (CEP-701)
- Linifanib (ABT-869)
- Linsitinib (OSI-906)
- Lorvotuzumab mertansine (BB-10901)
- Lutetium-177-PSMA-617
- LY-3023414
M
- Magrolimab (Hu5F9-G4)
- Mapatumumab (HGS-ETR1)
- Masitinib (AB-1010)
- MCARH-109
- Mezigdomide (BMS-986348)
- Milataxel (TL-139)
- MK-2206
- Mocetinostat (MGCD-0103)
- Motesanib (AMG-706)
N
O
- Oblimersen (Genasense)
- Olaptesed pegol (NOX-A12)
- Onartuzumab (MetMAb)
- Oprozomib (ONX-0912)
- Orteronel (TAK-700)
- Osocimab (BAY-1213790)
- Otlertuzumab (TRU-016)
P
- Patritumab deruxtecan (U3-1402)
- Pentraxin 2 (PRM-151)
- Perifosine (KRX-0401)
- Phosphomannopentaose sulfate (PI-88)
- Pictilisib (GDC-0941)
- Pidilizumab (CT-011)
- Pimitespib (TAS-116)
- Pinatuzumab vedotin (DCDT-2980S)
- Plinabulin (NPI-2358)
- Pracinostat (SB-939)
Q
R
- Rebimastat (BMS-275291)
- Refametinib (BAY-869766)
- Reovirus (Reolysin)
- Retaspimycin (IPI-504)
- Revumenib (SNDX-5613)
- Rezvilutamide (SHR-3680)
- Ricolinostat (ACY-1215)
- Ridaforolimus (AP-23573)
- Rilotumumab (AMG-102)
- Ripertamab (SCT-400)
- Rociletinib (CO-1686)
S
- Sapacitabine (CS-682)
- Sapanisertib (MLN-0128)
- Seliciclib (CYC-202)
- Semuloparin (AVE-5026)
- Spebrutinib (CC-292)
- Surufatinib (HMPL-012)
T
- Tabalumab (LY-2127399)
- Tasadenoturev (DNX-2401)
- Telisotuzumab vedotin (ABBV-399)
- Tertomotide (GV-1001)
- Tesetaxel (DJ-927)
- Tesevatinib (XL-647)
- Tigatuzumab (CS-1008)
- Tipifarnib (Zarnestra)
- Tirapazamine (Tirazone)
- Tislelizumab (Baizean)
- Tivantinib (ARQ-197)
- Tivozanib (AV-951)
- Tosedostat (CHR-2797)
- Trebananib (AMG-386)
- Tusamitamab ravtansine (SAR-408701)
U
V
- Vadastuximab talirine (SGN-CD33A)
- Vadimezan (AS-A404)
- Varlilumab (CDX-1127)
- Veliparib (ABT-888)
- Veltuzumab (hA20)
- Volasertib (BI-6727)
- Vorasidenib (AG-881)
- Vorolanib (CM-082)
- Vosaroxin (SNS-595)
- Voxtalisib (XL-765)
Z
Supportive and other medications
This section contains supportive drugs that are either approved or investigational. Biosimilars are also indexed here, indented below their parent compound. Note that EMA biosimilar approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound.
A
- Abciximab (ReoPro)
- Acetaminophen (Tylenol)
- Acetazolamide (Diamox)
- Acyclovir (Zovirax)
- ADAMTS13, recombinant (Adzynma)
- Alendronate (Fosamax)
- Alizapride (Litican)
- Allopurinol (Zyloprim)
- Alprazolam (Xanax)
- Aminocaproic acid (Amicar)
- Amoxicillin
- Anagrelide (Agrylin)
- Andexanet alfa (Andexxa)
- Anti-inhibitor coagulant complex (FEIBA NF)
- Antithrombin III (human and recombinant)
- Antithymocyte globulin, horse ATG (Atgam)
- Antithymocyte globulin, rabbit ATG (Grafalon)
- Antithymocyte globulin, rabbit ATG (Thymoglobulin)
- Apixaban (Eliquis)
- Aprepitant (Emend)
- Argatroban (Acova)
- Aripiprazole (Abilify)
- Ascorbic acid (Vitamin C)
- Aspirin
- Aspirin and dipyridamole (Aggrenox)
- Atropine (Atropen)
- Atovaquone (Mepron)
- Avatrombopag (Doptelet)
- Azathioprine (Imuran)
B
- Betibeglogene autotemcel (Zynteglo)
- Betrixaban (Bevyxxa)
- Bismuth subsalicylate (Pepto-Bismol)
- Bivalirudin (Angiomax)
C
- Cangrelor (Kengreal)
- Calcium phosphate rinse (Caphosol)
- Caspofungin (Cancidas)
- Cetirizine (Zyrtec)
- Chlorpheniramine (Chlor-Trimeton)
- Cilostazol (Pletal)
- Cimetidine (Tagamet)
- Ciprofloxacin (Cipro)
- Clarithromycin (Biaxin)
- Clemastine (Tavist)
- Clodronate (Bonefos)
- Clopidogrel (Plavix)
- Concizumab (Alhemo)
- Crizanlizumab (Adakveo)
- Cyanocobalamin (Vitamin B12)
- Cyclosporine
- Cytomegalovirus Immune Globulin (Cytogam)
D
- Dabigatran (Pradaxa)
- Dalteparin (Fragmin)
- Danazol (Danocrine)
- Dapsone (Aczone)
- Darbepoetin alfa (Aranesp)
- Deferasirox (Exjade)
- Deferasirox (Jadenu)
- Deferiprone (Ferriprox)
- Deferoxamine (Desferal)
- Defibrotide (Defitelio)
- Denosumab (Xgeva)
- Desmopressin (DDAVP)
- Dexchlorpheniramine (Polaramine)
- Dexrazoxane (Zinecard)
- Diphenhydramine (Benadryl)
- Dipyridamole (Persantine)
- Docusate (Colace)
- Dolasetron (Anzemet)
- Domperidone (Motilium)
- Doxycycline
- Dronabinol (Marinol)
E
- Eculizumab (Soliris)
- Edoxaban (Savaysa)
- Efanesoctocog alfa (Altuviiio)
- Eflapegrastim (Rolvedon)
- Eltrombopag (Promacta)
- Emicizumab (Hemlibra)
- Enoxaparin (Lovenox)
- Epoetin alfa (Procrit)
- Epoetin theta (Biopoin)
- Epoetin zeta (Eprex)
- Eptifibatide (Integrilin)
- Etranacogene dezaparvovec (Hemgenix)
- Exagamglogene autotemcel (Casgevy) FDA approved on 2023-12-08
F
- Factor VIIa, recombinant (NovoSeven RT)
- Factor VIII, human
- Factor VIII, recombinant
- Factor IX, human
- Factor IX, recombinant
- Factor IX, recombinant, Fc fusion protein (Alprolix)
- Factor X, human (Coagadex)
- Factor XIII concentrate, human (Corifact)
- Famciclovir (Famvir)
- Famotidine (Pepcid)
- Ferric carboxymaltose (Injectafer)
- Ferric derisomaltose (Monoferric)
- Ferric gluconate (Ferrlecit)
- Ferrous sulfate (Feosol)
- Ferumoxytol (Feraheme)
- Fibrinogen concentrate, human (RiaSTAP)
- Filgrastim (Neupogen)
- Finasteride (Proscar)
- Fitusiran (ALN-AT3SC)
- Fluconazole (Diflucan)
- Folic acid (Folate)
- Fondaparinux (Arixtra)
- Fosaprepitant (Emend for Injection)
- Fosnetupitant (Arokaris)
- Furosemide (Lasix)
G
H
I
- Ibandronate (Boniva)
- Idarucizumab (Praxbind)
- Indomethacin (Indocin)
- Iptacopan (Fabhalta) FDA approved 2023-12-05
- Iron dextran (INFeD)
- Iron sucrose (Venofer)
- Itraconazole (Sporanox)
L
- Lactulose
- Lamivudine (Epivir)
- Lansoprazole (Prevacid)
- Lenograstim (Granocyte)
- Lepirudin (Refludan) discontinued
- Letermovir (Prevymis)
- Levofloxacin (Levaquin)
- L-glutamine (Endari)
- Lipefilgrastim (Lonquex)
- Loperamide (Imodium)
- Lorazepam (Ativan)
- Lovotibeglogene autotemcel (Lyfgenia) FDA approved on 2023-12-08
- Luspatercept (Reblozyl)
- Lusutrombopag (Mulpleta)
M
- Mannitol
- Meperidine (Demerol)
- Mesna (Mesnex)
- Methyltesterone (Android)
- Metoclopramide (Reglan)
- Mitapivat (Pyrukynd)
- Motixafortide (Aphexda) FDA approved 2023-09
- Mycophenolate mofetil (CellCept)
N
O
- Olanzapine (Zyprexa)
- Omeprazole (Prilosec)
- Omidubicel (Omisirge) FDA approved 2023-04-17
- Ondansetron (Zofran)
- Oprelvekin (Neumega)
P
- Palifermin (Kepivance)
- Palonosetron (Aloxi)
- Pamidronate (Aredia)
- Pantoprazole (Protonix)
- Pegfilgrastim (Neulasta)
- Pegfilgrastim-apgf (Nyvepria)
- Pegfilgrastim-bmez (Ziextenzo)
- Pegfilgrastim-cbqv (Udenyca)
- Pegfilgrastim-fpgk (Stimufend)
- Pegfilgrastim-jmdb (Fulphila)
- Pegfilgrastim-cegf (Cegfila)
- Pegfilgrastim-gras (Grasustek)
- Pegfilgrastim-pbbk (Fylnetra)
- Pegfilgrastim-pelg (Pelgraz)
- Pegfilgrastim-pelm (Pelmeg)
- Pegfilgrastim-stim (Stimufend)
- Penicillin V
- Pentamidine (Nebupent)
- Phenytoin (Dilantin)
- Phytonadione (Vitamin K)
- Plerixafor (Mozobil)
- Prasugrel (Effient)
- Pravastatin (Pravachol)
- Prochlorperazine (Compazine)
- Promethazine (Phenergan)
- Protamine sulfate
- Protein C, human (Ceprotin)
- Prothrombin Complex Concentrate, human
Q
R
- Rabeprazole (Aciphex)
- Raloxifene (Evista)
- Ramosetron (Iribo)
- Ranitidine (Zantac)
- Rasburicase (Elitek)
- Remestemcel-L (Prochymal)
- Rho(D) immune globulin (RhoGAM)
- Rilzabrutinib (PRN-1008)
- Risedronate (Actonel)
- Rivaroxaban (Xarelto)
- Rolapitant (Varubi)
- Romiplostim (Nplate)
- Rusfertide (PTG-300)
S
- Sargramostim (Leukine)
- Scopolamine (Scopoderm)
- Sennosides (Senna)
- Siltuximab (Sylvant)
- Sirolimus (Rapamune)
- Sodium thiosulfate (Pedmark)
- Sutimlimab (Enjaymo)
T
- Tacrolimus (Prograf)
- Tbo-filgrastim (Granix)
- Telotristat (Xermelo)
- Ticagrelor (Brilinta)
- Ticlopidine (Ticlid)
- Tinzaparin (Innohep)
- Tirofiban (Aggrastat)
- Tocilizumab (Actemra)
- Tofacitinib (Xeljanz)
- Tranexamic acid (Cyklokapron)
- Trilaciclib (Cosela)
- Trimethoprim-Sulfamethoxazole (Bactrim DS)
- Tropisetron (Navoban)
U
V
- Valacyclovir (Valtrex)
- Valganciclovir (Valcyte)
- Valoctocogene roxaparvovec (AAV5-hFVIII-SQ)
- Valproate (Depakote)
- Verbrinacogene setparvovec (FLT-180a)
- von Willebrand factor and factor VIII complex, human
- von Willebrand factor, recombinant
- Vonoprazan (Takecab)
- Vorapaxar (Zontivity)
- Voriconazole (Vfend)
W
Z
By Category
Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is an ongoing process so not all of these links are active or current).
Drugs in a REMS program
Cytotoxic Chemotherapy
- Alkylating agents
- Anthracyclines
- Antimetabolites
- DNA synthesis inhibitors
- Microtubule inhibitors
- Nitrogen mustards
- Nitrosureas
- Platinum agents
- Proteasome inhibitors
- Taxanes
- Topoisomerase inhibitors
- Vinca alkaloids
Kinase inhibitors
- AKT1 inhibitors
- ALK inhibitors
- Aurora kinase inhibitors
- AXL inhibitors
- Bcr-Abl inhibitors
- BRAF inhibitors
- BTK inhibitors
- CDK inhibitors
- EGFR inhibitors
- ERBB2 inhibitors
- ERBB4 inhibitors
- FGFR inhibitors
- FLT3 inhibitors
- IGFR inhibitors
- JAK inhibitors
- KIT inhibitors
- MEK inhibitors
- MET inhibitors
- mTOR inhibitors
- PDGFR inhibitors
- PI3K inhibitors
- PLK1 inhibitors
- RET inhibitors
- ROS1 inhibitors
- SRC inhibitors
- SYK inhibitors
- TEK inhibitors
- TRK inhibitors
- VEGF inhibitors
Endocrine therapy
- Antiandrogens
- Steroid synthesis inhibitors
- Androgen receptor inhibitors
- 5 alpha-reductase inhibitors
- GnRH agonists
- GnRH antagonists
- Aromatase inhibitors
- Selective estrogen receptor modulators
- Steroids
- Somatostatin analogs
Investigational and Discontinued
Biologics
- Antibody medications
- Antibody-drug conjugates
- Anti-HER2 medications
- IL-6 inhibitors
- Enzymes
- Immunotherapy
- Immunomodulatory drugs (IMiDs)
Supportive Medications
- Antibacterials
- Antidiarrheals
- Antifungals
- Antihistamines
- Antivirals
- Bisphosphonates
- Chemotherapy protective agents
- Emesis prevention
- PCP prophylaxis
- RANK ligand inhibitors
- Steroids
Radioactive agents
Benign Hematology Medications
Hematopoietic Growth Factors
Miscellaneous
- Drugs in a REMS program
- HDAC inhibitors
- Hypomethylating agents
- Retinoids
- WHO Essential Cancer Medicines
Medications by Condition
- Acute lymphocytic leukemia medications
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Anal cancer medications
- Anaplastic large cell lymphoma medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- Cancer of unknown primary medications
- Castleman disease medications
- Central nervous system (CNS) cancer medications
- Central nervous system (CNS) lymphoma medications
- Cervical cancer medications
- Chronic lymphocytic leukemia (CLL/SLL) medications
- Chronic myeloid leukemia (CML) medications
- Chronic myelomonocytic leukemia (CMML) medications
- Colon cancer medications
- Colorectal cancer (CRC) medications
- Cutaneous BCC medications
- Cutaneous SCC medications
- Cutaneous T-cell lymphoma medications
- Diffuse large B-cell lymphoma medications
- Endometrial cancer medications
- Esophageal cancer medications
- Essential thrombocythemia medications
- Extranodal NK/T-cell lymphoma, nasal type lymphoma medications
- Follicular lymphoma medications
- Gastric cancer medications
- Hairy cell leukemia medications
- Head and neck cancer medications
- Hepatobiliary cancer medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Immune thrombocytopenic purpura (ITP) medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Melanoma medications
- Mesothelioma medications
- Multiple myeloma medications
- Myelodysplastic syndrome medications
- Myelofibrosis medications
- NK/T-cell lymphoma medications
- Non-small cell lung cancer medications
- Neuroendocrine tumor medications
- Ovarian cancer medications
- Pancreatic cancer medications
- Paroxysmal nocturnal hemoglobinuria (PNH) medications
- Penile cancer medications
- Peripheral T-cell lymphoma medications
- Plasma cell leukemia medications
- Polycythemia vera medications
- Primary mediastinal B-cell lymphoma medications
- Prostate cancer medications
- Rectal cancer medications
- Renal cell carcinoma medications
- Sarcoma medications
- Sickle cell anemia medications
- Small cell lung cancer medications
- T-cell lymphoma medications
- Testicular cancer medications
- Thymoma medications
- Thyroid cancer medications
- Transformed lymphoma medications
- Transplant medications
- Waldenström macroglobulinemia medications
Medications by Route of Administration
- Intraarterial (IA) medications
- Intracavitary medications
- Intramuscular (IM) medications
- Intrathecal (IT) medications
- Intravenous (IV) medications
- Intravesicular medications
- Oral (PO) medications
- Subcutaneous (SC) medications
Medications by FDA Year of Approval
- FDA approved in 1939
- FDA approved in 1941
- FDA approved in 1946
- FDA approved in 1949
- FDA approved in 1951
- FDA approved in 1952
- FDA approved in 1953
- FDA approved in 1954
- FDA approved in 1955
- FDA approved in 1956
- FDA approved in 1957
- FDA approved in 1958
- FDA approved in 1959
- FDA approved in 1962
- FDA approved in 1963
- FDA approved in 1964
- FDA approved in 1965
- FDA approved in 1966
- FDA approved in 1967
- FDA approved in 1968
- FDA approved in 1969
- FDA approved in 1970
- FDA approved in 1971
- FDA approved in 1973
- FDA approved in 1974
- FDA approved in 1975
- FDA approved in 1976
- FDA approved in 1977
- FDA approved in 1978
- FDA approved in 1979
- FDA approved in 1980
- FDA approved in 1981
- FDA approved in 1982
- FDA approved in 1983
- FDA approved in 1984
- FDA approved in 1985
- FDA approved in 1986
- FDA approved in 1987
- FDA approved in 1988
- FDA approved in 1989
- FDA approved in 1990
- FDA approved in 1991
- FDA approved in 1992
- FDA approved in 1993
- FDA approved in 1994
- FDA approved in 1995
- FDA approved in 1996
- FDA approved in 1997
- FDA approved in 1998
- FDA approved in 1999
- FDA approved in 2000
- FDA approved in 2001
- FDA approved in 2002
- FDA approved in 2003
- FDA approved in 2004
- FDA approved in 2005
- FDA approved in 2006
- FDA approved in 2007
- FDA approved in 2008
- FDA approved in 2009
- FDA approved in 2010
- FDA approved in 2011
- FDA approved in 2012
- FDA approved in 2013
- FDA approved in 2014
- FDA approved in 2015
- FDA approved in 2016
- FDA approved in 2017
- FDA approved in 2018
- FDA approved in 2019
- FDA approved in 2020
- FDA approved in 2021
- FDA approved in 2022
- FDA approved in 2023
- FDA approved in 2024
Interesting and Helpful Links
- Antidepressants and other psychiatric medications in cancer care
- Antiemetic support
- Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline (2013)
- 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society (ASCO/ONS) Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology
- Chemotherapy Administration Sequence[3] - with chemotherapy sequencing chart
- The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. PubMed
- CredibleMeds.org - lists of QT-prolonging drugs; requires free registration to see full list
- FDA drug shortages list
- ASHP drug shortages list - also includes information about discontinued drugs
- DailyMed - a comprehensive NLM portal to all FDA-approved drugs
- Drugs@FDA - the main portal into the FDA drug database
- The NCI Drug Dictionary - an extensive resource with most antineoplastics (approved and in clinical trials) listed
- In the Pipeline - a blog from a veteran of the pharmaceutical industry, Derek Lowe. General but much is cancer-relevant. The old home of this blog is no longer active.
- Steroid conversions
- Vesicant & irritant chemotherapy
- Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers
- CPIC Guidelines The Clinical Pharmacogenetics Implementation Consortium provides guidelines for a small set of drugs with pharmacogenetically-guided dosing implications, some of which are oncologics
References
- ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
- ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13. link to original article PubMed
- ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article